Anti-Human CTLA-4 (Ipilimumab) – HRP
Anti-Human CTLA-4 (Ipilimumab) – HRP
Product No.: LT1602
Product No.LT1602 Clone MDX-010 Target CTLA-4 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3 Isotype Human IgG1κ Applications ELISA , FC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Human CTLA-4 Product Concentration 0.5 mg/ml Formulation This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase) Storage and Handling This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893921 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Ipilimumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA Additional Reported Applications For Relevant Conjugates ? B CyTOF® Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for research use only. Background Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body’s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body’s own immune response against cancer cells.”2 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.1 This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects. Antigen Distribution CTLA4 is constitutively expressed in regulatory T cells. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Ipilimumab biosimilars are used as calibration standards or reference controls in pharmacokinetic (PK) bridging ELISA assays to quantify Ipilimumab drug concentrations in serum samples by providing a known, validated comparator that allows for accurate quantitation of the antibody in patient samples. In a typical PK bridging ELISA for Ipilimumab:
Reference controls (known concentrations of Ipilimumab) are also included in each run to confirm assay consistency and validity. Essential details:
Summary table: Role of Ipilimumab biosimilars in ELISA PK quantitation
References to ELISA protocols and standards:
This methodology is essential for clinical pharmacokinetic monitoring, dose rationalization, and quality assurance in Ipilimumab therapy studies. Biopharma companies use an extensive suite of analytical assays to confirm the structural and functional similarity of a proposed biosimilar to the originator drug. These assays include methods for characterizing primary and higher-order structure, detecting posttranslational modifications, ensuring purity, and testing biological activity and potency. Core analytical assays commonly performed:
Functional Assays Focus:Functional assessments address whether any minor structural differences impact clinical efficacy or biological activity. For example, binding assays can demonstrate that a biosimilar antibody binds its target antigen and Fc receptors with the same affinity as the originator. Multiple, orthogonal assays are used to cover all relevant biological activities because "function follows form," and the ultimate goal is no clinically meaningful differences in action. Role of Leinco Biosimilar Products:Leinco is a provider of biosimilar antibodies and proteins commonly used as reference standards or controls in these assays. Specifically:
In summary, biosimilar development relies on a comprehensive analytical and functional comparability package, where structural and biological similarity must be proven using highly sensitive, orthogonal assays, and reference biosimilars such as those from Leinco support this rigorous benchmarking process. References & Citations1. Wolchok, JD. et al. (2013) N Engl J Med 369(2):122-33. 2. Soo, RA. et al. (2017) Lancet Oncol. 18(12):e731-e741. 3. Lipson, EJ. and Drake, CG. (2011) Clin Cancer Res 17(22):6958-62. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
LT1600 | |
LT1602 | |
LT1601 | |
LT1606 | |
LT1605 | |
LT1607 |
